BridgeBio Oncology Therapeutics, Inc. (BBOT)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.80
- As of
Kresmion compiles this page from BBOT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BridgeBio Oncology Therapeutics, Inc. (BBOT): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
See the full BBOT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BBOT on one page. Preview it with sample data, then open it live with a free account.
Preview the BBOT dossierActive events for BBOT
- mediumEarnings below estimates
Q2-2026: Missed consensus by 23.1%, EPS $-0.71 vs $-0.5766 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +167495% to BBOT (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 60% of BBOT (2026Q2)
- medium13F: new position
TWO SIGMA INVESTMENTS, LP new position in BBOT
- mediumEarnings below estimates
Q3-2025: Missed consensus by 159.1% - EPS $-1.03 vs $-0.3976 estimate
FREE, NO ACCOUNT
Every event on BBOT, as it fires
You are seeing 5 of 6 events recorded on BBOT since 2026-06-10.
The five above landed across 3 days. The other 1 were recorded on those same days. 3 of the 6 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BBOT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 107924102 · 2026Q2 | $19.9M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 107924102 · 2026Q2 | $804K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 107924102 · 2026Q2 | $447K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 107924102 · 2026Q2 | $202K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BBOT
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BBOT against its peers
BBOT's return on equity of -32.6% ranks in the 60th percentile of 23 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | BBOT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 13.9M | n/a | 15 |
| Gross margin | n/a | 64.3% | n/a | 5 |
| Operating margin | n/a | -616.4% | n/a | 14 |
| Net margin | n/a | -574.5% | n/a | 15 |
| Return on equity | -32.6% | -56.3% | 60 | 23 |
Peers (24): ZNTL, CAMP, KROS, PLX, IKT, ALEC, PYXS, SLGL, LXEO, IFRX, LYEL, PALI, GLSI, SION, NAGE, EVMN, ACIU, IMRX, VNDA, YARW, RNAC, ELDN, LRMR, CGEN. Left out: SCNLD (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (BBOT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BBOT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BBOT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.